HLS Therapeutics Inc. (TSX:HLS)
Canada · Delayed Price · Currency is CAD 3.790
+0.090 (2.43%)
Aug 28, 2026, 3:59 PM EST
HLS Therapeutics Ratios and Metrics
Market cap in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 117 | 151 | 125 | 127 | 318 | 487 | |
Market Cap Growth | -28.86% | 20.64% | -1.37% | -60.20% | -34.60% | -14.81% |
Enterprise Value | 157 | 211 | 194 | 220 | 426 | 586 |
Last Close Price | 3.79 | 4.82 | 3.93 | 3.95 | 9.69 | 14.56 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 50.92 | 50.92 | 50.92 | 50.92 | 185.98 |
PS Ratio | 1.47 | 1.98 | 1.53 | 1.52 | 3.83 | 6.41 |
PB Ratio | 1.49 | 1.78 | 1.22 | 0.98 | 1.88 | 2.39 |
P/FCF Ratio | 4.55 | 6.50 | 10.87 | 6.09 | 13.92 | 23.48 |
P/OCF Ratio | 4.52 | 6.42 | 10.85 | 6.08 | 13.88 | 23.41 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.97 | 2.77 | 2.38 | 2.64 | 5.12 | 7.71 |
EV/EBITDA Ratio | 6.32 | 8.95 | 9.26 | 7.74 | 15.14 | 19.78 |
EV/FCF Ratio | 6.10 | 9.10 | 16.88 | 10.57 | 18.63 | 28.26 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.76 | 0.81 | 0.93 | 0.90 | 0.78 | 0.61 |
Debt / EBITDA Ratio | 2.39 | 2.81 | 4.42 | 4.06 | 4.66 | 4.07 |
Debt / FCF Ratio | 2.31 | 2.94 | 8.32 | 5.56 | 5.76 | 5.96 |
Net Debt / Equity Ratio | 0.51 | 0.62 | 0.69 | 0.67 | 0.61 | 0.48 |
Net Debt / EBITDA Ratio | 1.66 | 2.22 | 3.37 | 3.05 | 3.68 | 3.26 |
Net Debt / FCF Ratio | 1.55 | 2.25 | 6.13 | 4.17 | 4.54 | 4.66 |
Asset Turnover | 0.41 | 0.37 | 0.31 | 0.28 | 0.24 | 0.21 |
Inventory Turnover | 2.60 | 1.84 | 1.58 | 1.43 | 1.20 | 0.99 |
Quick Ratio | 0.76 | 0.75 | 1.11 | 1.22 | 1.02 | 1.18 |
Current Ratio | 1.05 | 1.11 | 1.57 | 1.65 | 1.42 | 1.58 |
Return on Equity (ROE) | -14.07% | -18.69% | -23.25% | -24.69% | -16.50% | -7.95% |
Return on Assets (ROA) | -2.03% | -1.73% | -2.60% | -2.87% | -3.26% | -1.35% |
Return on Capital Employed (ROCE) | -4.50% | -3.70% | -5.60% | -5.70% | -6.40% | -2.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -10.38% | -11.31% | -22.63% | -28.70% | -10.03% | -3.41% |
FCF Yield | 21.99% | 15.39% | 9.20% | 16.42% | 7.18% | 4.26% |
Dividend Yield | - | - | - | 2.53% | 2.06% | 1.37% |
Buyback Yield / Dilution | 1.42% | 0.98% | 1.31% | 0.52% | -0.77% | -1.48% |
Total Shareholder Return | 1.42% | 0.98% | 1.31% | 3.06% | 1.29% | -0.11% |